Invion’s licensed PhotosoftTM technology receives patent protection until 2033 PhotosoftTM targeted as a therapy for a range of cancers including ovarian, lung, skin and prostate cancer Melbourne, Australia, 10 September 2018: ASX-listed life sciences company Invion Limited (ASX:IVX) announces the grant in Australia of the patent for chlorin e4 sodium, a new generation photodynamic therapy…
Read more
Invion to spinout respiratory assets and advance clinical development in China
Invion to demerge respiratory assets into stand-alone company, Chronic Airway Therapeutics Limited (CAT) CAT to focus on development of respiratory assets in China, expediting advancement into Phase 3 clinical trials Eligible Invion shareholders will, on completion of the demerger, receive one share in Chronic Airway Therapeutics Limited for each Invion share they hold Melbourne, Australia…
Read more
Photosoft efficiently destroys ovarian cancer cells in vitro
Invion and Hudson Institute of Medical Research are collaborating on R&D projects for the PhotosoftTM technology as a treatment of a range of cancers PhotosoftTM characterisation studies have been completed in multiple ovarian cancer cell lines PhotosoftTM caused efficient and highly effective cancer cell destruction in vitro Melbourne, Australia, 5 July 2018: Invion Limited (ASX:…
Read more
Financial Report for the year ended 30 June 2018
Invion is pleased to lodge it’s Financial Report, Corporate Governance Statement and Appendix 4G for the year ended 30 June 2018. Financial Report for the year ended 30 June 2018
Read more